Pfizer is ringing the changes as it exits the second quarter, tossing out a midstage pneumococcal vaccine candidate and a handful of phase 1 assets including a respiratory syncytial virus (RSV) prospect it picked up in last year’s ReViral takeover.

辉瑞公司在第二季度退出时正在敲响这一变化，淘汰了中期肺炎球菌疫苗候选人和包括呼吸道合胞病毒（RSV）在内的少数第一阶段资产，预计它将在去年的修订收购中获得。

The quarterly pipeline update (PDF) features the removal of two phase 2 assets, including the previously disclosed defenestration of its oral obesity and diabetes candidate lotiglipron over safety concerns. The other phase 2 candidate to get the ax in the update is PF-06842433, a vaccine that was in development for the prevention of invasive and noninvasive pneumococcal infections in infants and children..

季度管道更新（PDF）的特点是删除了两个第二阶段资产，包括之前披露的口腔肥胖和糖尿病候选人lotiglipron的安全问题。在更新中获得ax的另一个2期候选者是PF-06842433，该疫苗正在开发中，用于预防婴儿和儿童的侵入性和非侵入性肺炎球菌感染。。

Pfizer ran (PDF) a phase 1/2 clinical trial of the seven-valent pneumococcal conjugate vaccine from 2018 to 2020. The vaccine candidate was designed to complement the pneumococcal coverage provided by Prevnar 13, but, with Prevnar 20 now approved, Pfizer has moved on from the program.

辉瑞运行（PDF）2018年至2020年七价肺炎球菌结合疫苗的1/2期临床试验。候选疫苗旨在补充Prevnar 13提供的肺炎球菌覆盖率，但随着Prevnar 20现已获得批准，辉瑞公司已从该计划中继续发展。

The update also covers the discontinuation of six phase 1 assets, including PF-07923567. The N-protein inhibitor, also known as RV-299, is one of the RSV candidates that Pfizer added to its pipeline in a deal to buy ReViral for $436 million upfront last year. Work on the most advanced program included in the deal, sisunatovir, continues, but Pfizer has decided it can do without PF-07923567..

更新还包括终止六项第一阶段资产，包括PF-07923567。N蛋白抑制剂，也称为RV-299，是辉瑞公司去年提前购买4.36亿美元的交易中加入其管道的RSV候选人之一。交易中包含的最先进的项目sisunatovir仍在继续，但辉瑞公司已决定无需PF-07923567即可完成。。

Pfizer is also jettisoning a pair of atopic dermatitis programs and another pair of solid tumor assets. In atopic dermatitis, the Big Pharma followed up the discontinuation of one topical “soft” JAK inhibitor last year by axing a similar molecule that it was studying in the same phase 1 trial. Alongside that, it has cut PF-07242813, a CD1a inhibitor, after wrapping up a phase 1 trial in healthy volunteers and atopic dermatitis patients..

辉瑞公司也放弃了一对特应性皮炎项目和另一对实体肿瘤资产。在特应性皮炎中，大制药公司去年通过使用其在同一1期临床试验中研究的类似分子来跟踪一种局部“软”JAK抑制剂的停药。除此之外，它还在健康志愿者和特应性皮炎患者中进行了1期临床试验后，削减了CD1a抑制剂PF-07242813。。

The solid tumor discontinuations fall on the AXL/MERTK inhibitor PF-07265807 and the IL15 activator PF-07209960. Pfizer acquired the AXL/MERTK inhibitor in the Array BioPharma buyout, but evidence the mechanism lowers the immune activation threshold and boosts anti-tumor immunity has failed to yield a clinical candidate the drugmaker thinks warrants further development..

实体瘤中断落在AXL/MERTK抑制剂PF-07265807和IL15激活剂PF-07209960上。辉瑞在Array BioPharma收购中收购了AXL/MERTK抑制剂，但证据表明该机制降低了免疫激活阈值并提高了抗肿瘤免疫力未能产生药物制造商认为值得进一步开发的临床候选药物。。

Finally, Pfizer has thinned its sickle cell pipeline 10 months after its buyout of Global Blood Therapeutics positioned it as a force in the indication. The discontinuation affects PF-07209326, an anti-E-selectin inhibitor that was in development at Pfizer prior to the Global Blood takeover. The confirmation follows the news last week that Pfizer is walking away from a sickle cell disease licensing deal with Syros Pharmaceuticals that it inherited from its takeover of Global Blood..

最后，辉瑞在收购全球血液治疗公司10个月后将其镰状细胞管道缩小为适应症的力量。停药影响PF-07209326，一种抗E-选择素抑制剂，在全球血液收购之前正在辉瑞公司开发。这一确认是在上周有消息称辉瑞正在摆脱与Syros制药公司收购全球血液的镰状细胞病许可协议。。